Fundraising Fox
DMC Biotechnologies
Boulder, US · Founded 2014 · 42 employees on LinkedIn · 10 known investors
Find your way into DMC Biotechnologies
Sign up to find every way you can get introduced to DMC Biotechnologies
- Your email: who you already know at DMC Biotechnologies, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the DMC Biotechnologies team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols. It serves specialty chemical, nutraceutical, and industrial customers seeking sustainable, cost-competitive alternatives to conventional chemical supply chains.
Founders & leadership
DMC Biotechnologies was founded in 2014 by Matthew Lipscomb.
Board
Investors · 10
How we know: funding news · sofinnovapartners.com · Not right? Tell us
How we know: CIBUS ENTERPRISE FUND II LP's portfolio page · Not right? Tell us
How we know: Sofinnova Partners's portfolio page · funding news · sofinnovapartners.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · sofinnovapartners.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Also in the syndicate · 4
Reported raises · per SEC filings
Form D private placements$48.1M disclosed across 8 rounds · 2018–2025
▶$1.4MraisedDec 2025 · 7 investors · BiotechnologyRule 506(b)
- Josh YelenExecutive Officer
- Josko BobanovicDirector
- Rob van der MeijDirector
- K'Lynne JohnsonDirector
- Alastair CooperDirector
- Jim FlattExecutive Officer, Director
- Doug CameronDirector
- Matthew LipscombDirector
- Offering amount
- $2.5M
- Amount sold
- $1.4M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$904.5KraisedDec 2025 · 4 investors · BiotechnologyRule 506(b)
- Rob van der MeijDirector
- Josh YelenExecutive Officer
- Alastair CooperDirector
- K'Lynne JohnsonDirector
- Matthew LipscombDirector
- Jim FlattExecutive Officer, Director
- Doug CameronDirector
- Josko BobanovicDirector
- Offering amount
- $1.7M
- Amount sold
- $904.5K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.8MraisedApr 2025 · 9 investors · BiotechnologyRule 506(b)
- Doug CameronDirector
- Rob van der MeijDirector
- K'Lynne JohnsonDirector
- Josh YelenExecutive Officer
- Alastair CooperDirector
- Matthew LipscombDirector
- Jim FlattExecutive Officer, Director
- Josko BobanovicDirector
- Offering amount
- $10M
- Amount sold
- $4.8M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66.7KraisedAug 2022 · 1 investors · BiotechnologyRule 506(b)
- Doug CameronDirector
- Josko BobanovicDirector
- Carolyn FritzDirector
- Michael D. LynchDirector
- Matthew LipscombExecutive Officer, Director
- Rob van der MeijDirector
- Ashley JenkinsExecutive Officer
- Alastair CooperDirector
- Offering amount
- $66.7K
- Amount sold
- $66.7K
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$33.8MraisedDec 2021 · 12 investors · BiotechnologyRule 506(b)
- Doug CameronDirector
- Alastair CooperDirector
- Rob van der MeijDirector
- Josko BobanovicDirector
- Matthew LipscombExecutive Officer, Director
- Carolyn FritzDirector
- Michael D. LynchDirector
- Offering amount
- $43.5M
- Amount sold
- $33.8M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$22.4KraisedJan 2021 · 1 investors · BiotechnologyRule 506(b)
- Josko BobanovicDirector
- Rob van der MeijDirector
- Carolyn FritzDirector
- Michael D. LynchDirector
- Matthew LipscombExecutive Officer, Director
- Doug CameronDirector
- Offering amount
- $22.4K
- Amount sold
- $22.4K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4.6MraisedJun 2019 · 3 investors · BiotechnologyRule 506(b)
- Rob van der MeijDirector
- Josko BobanovicDirector
- Michael D. LynchDirector
- Carolyn FritzDirector
- Matthew LipscombExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $4.6M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.5MraisedMar 2019 · 3 investors · BiotechnologyRule 506(b)
- Michael D. LynchDirector
- Rob van der MeijDirector
- Matthew L. LipscombExecutive Officer, Director
- Carolyn FritzDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2017 | $600K |
| Department of Agriculture (USDA) | Phase I | 2017 | $100K |
| National Science Foundation | Phase ISTTR | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does DMC Biotechnologies do?
- DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols. It serves specialty chemical, nutraceutical, and industrial customers seeking sustainable, cost-competitive alternatives to conventional chemical supply chains.
- Who founded DMC Biotechnologies?
- DMC Biotechnologies was founded by Matthew Lipscomb in 2014.
- Who are DMC Biotechnologies's investors?
- DMC Biotechnologies's investors include Breakthrough Energy Ventures, CIBUS ENTERPRISE FUND II LP, Sofinnova Partners, Boulder Ventures, Capricorn Venture Partners, Michelin Ventures.
- How much funding has DMC Biotechnologies raised?
- DMC Biotechnologies has disclosed $48.1M raised across 8 rounds.
- Where is DMC Biotechnologies headquartered?
- DMC Biotechnologies is headquartered in Boulder, US.